These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Psychosis and synthetic cannabinoids. Deng H; Verrico CD; Kosten TR; Nielsen DA Psychiatry Res; 2018 Oct; 268():400-412. PubMed ID: 30125871 [TBL] [Abstract][Full Text] [Related]
24. Synthetic Cannabinoid Use in a Psychiatric Patient Population: A Pilot Study. Welter S; Lücke C; Lam AP; Custal C; Moeller S; Sörös P; Thiel CM; Philipsen A; Müller HHO Eur Addict Res; 2017; 23(4):182-193. PubMed ID: 28848170 [TBL] [Abstract][Full Text] [Related]
25. Self-injury - placement in mental disorders classifications, risk factors and primary mechanisms. Review of the literature. Lenkiewicz K; Racicka E; Bryńska A Psychiatr Pol; 2017 Apr; 51(2):323-334. PubMed ID: 28581540 [TBL] [Abstract][Full Text] [Related]
26. A Systematic Review of the Efficacy of Cannabinoid Agonist Replacement Therapy for Cannabis Withdrawal Symptoms. Werneck MA; Kortas GT; de Andrade AG; Castaldelli-Maia JM CNS Drugs; 2018 Dec; 32(12):1113-1129. PubMed ID: 30361897 [TBL] [Abstract][Full Text] [Related]
27. Synthetic cannabinoid use among college students. Mathews EM; Jeffries E; Hsieh C; Jones G; Buckner JD Addict Behav; 2019 Jun; 93():219-224. PubMed ID: 30772774 [TBL] [Abstract][Full Text] [Related]
28. Immune system: a possible nexus between cannabinoids and psychosis. Suárez-Pinilla P; López-Gil J; Crespo-Facorro B Brain Behav Immun; 2014 Aug; 40():269-82. PubMed ID: 24509089 [TBL] [Abstract][Full Text] [Related]
29. Synthetic and Non-synthetic Cannabinoid Drugs and Their Adverse Effects-A Review From Public Health Prospective. Cohen K; Weinstein AM Front Public Health; 2018; 6():162. PubMed ID: 29930934 [TBL] [Abstract][Full Text] [Related]
30. Prevalence and psychological correlates of occasional and repetitive deliberate self-harm in adolescents. Brunner R; Parzer P; Haffner J; Steen R; Roos J; Klett M; Resch F Arch Pediatr Adolesc Med; 2007 Jul; 161(7):641-9. PubMed ID: 17606826 [TBL] [Abstract][Full Text] [Related]
31. Impulsivity and self-harm in adolescence: a systematic review. Lockwood J; Daley D; Townsend E; Sayal K Eur Child Adolesc Psychiatry; 2017 Apr; 26(4):387-402. PubMed ID: 27815757 [TBL] [Abstract][Full Text] [Related]
32. Self-harm behavior among individuals with intermittent explosive disorder and personality disorders. Jenkins AL; McCloskey MS; Kulper D; Berman ME; Coccaro EF J Psychiatr Res; 2015 Jan; 60():125-31. PubMed ID: 25300440 [TBL] [Abstract][Full Text] [Related]
33. Health Risk Behaviors With Synthetic Cannabinoids Versus Marijuana. Clayton HB; Lowry R; Ashley C; Wolkin A; Grant AM Pediatrics; 2017 Apr; 139(4):. PubMed ID: 28289138 [TBL] [Abstract][Full Text] [Related]
34. Human Laboratory Studies on Cannabinoids and Psychosis. Sherif M; Radhakrishnan R; D'Souza DC; Ranganathan M Biol Psychiatry; 2016 Apr; 79(7):526-38. PubMed ID: 26970363 [TBL] [Abstract][Full Text] [Related]
35. Modulatory effects of cannabinoids on brain neurotransmission. Cohen K; Weizman A; Weinstein A Eur J Neurosci; 2019 Aug; 50(3):2322-2345. PubMed ID: 30882962 [TBL] [Abstract][Full Text] [Related]
36. Cannabinoids for Treatment of MS Symptoms: State of the Evidence. Rice J; Cameron M Curr Neurol Neurosci Rep; 2018 Jun; 18(8):50. PubMed ID: 29923025 [TBL] [Abstract][Full Text] [Related]
37. The associations between alexithymia and both non-suicidal self-injury and risky drinking: A systematic review and meta-analysis. Greene D; Boyes M; Hasking P J Affect Disord; 2020 Jan; 260():140-166. PubMed ID: 31494366 [TBL] [Abstract][Full Text] [Related]
38. The impact of the 2016 Psychoactive Substances Act on synthetic cannabinoid use within the homeless population: Markets, content and user harms. Ralphs R; Gray P; Sutcliffe OB Int J Drug Policy; 2021 Nov; 97():103305. PubMed ID: 34146792 [TBL] [Abstract][Full Text] [Related]